129118-11-2

Basic information

• Product Name: N-Methoxy-N-methylpentanamide
• Synonyms: N-Methoxy-N-methylpentanamide;N-Methylvalerohydroxamic acid methyl ester
• CAS NO: 129118-11-2
• Molecular Formula: C₇H₁₅NO₂
• Molecular Weight: 145.1995
• Mol File: 129118-11-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-Methoxy-N-methylpentanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methoxy-N-methylpentanamide(129118-11-2)
• EPA Substance Registry System: N-Methoxy-N-methylpentanamide(129118-11-2)

Safety Data

• Hazardous Substances Data: 129118-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Methoxy-N-methylpentanamide is used as a precursor in the synthesis of pharmaceuticals and other organic compounds for its ability to facilitate the creation of various medicinal agents.
Used in Chemical Synthesis:
N-Methoxy-N-methylpentanamide is used as a solvent in chemical synthesis processes, providing a medium for reactions to occur and potentially enhancing the efficiency of certain chemical reactions.
Used in Coatings, Adhesives, Sealants, and Elastomers Industry:
N-Methoxy-N-methylpentanamide has potential applications in the field of coatings, adhesives, sealants, and elastomers, where it may contribute to the properties of these materials, such as adhesion, flexibility, or durability.
Safety Note:
It is important to handle N-Methoxy-N-methylpentanamide with caution as it can cause irritation to the skin, eyes, and respiratory system. Proper safety measures should be taken during its use and handling.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 638-29-9 n-valeryl chloride 
• 84298-28-2 1H-1,2,3-benzotriazol-1-yl(n-butyl)methanone 
• 109-52-4 valeric acid 
• 693-04-9 butyl magnesium bromide 
• 109-72-8 n-butyllithium 
• 123707-26-6 N,N'-dimethoxy-N,N'-dimethyl urea 

Downstream Products

• 83666-06-2 5-Butyl-3-methyl-4-(phenylmethyl)isoxazole 
• 25870-62-6 1-phenyl-2-hexanone 
• 132-90-1 3-n-butyl-1(2H)-isoquinolinone 
• 7661-42-9 3-n-butylisoquinoline 
• 371151-24-5 3-butyl-2,5,6,7-tetrahydro-[2]pyrindin-1-one 
• 138344-08-8 [2-Methoxy-6-(2-oxo-hexyl)-phenyl]-carbamic acid tert-butyl ester 
• 138344-01-1 [4-Methoxy-2-(2-oxo-hexyl)-phenyl]-carbamic acid tert-butyl ester 
• 155955-79-6 1-<2-((tert-butoxycarbonyl)aminomethyl)phenyl>-2-hexanone 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

One-pot Unsymmetrical Ketone Synthesis Employing a Pyrrole-Bearing Formal Carbonyl Dication Linchpin Reagent

A one-pot procedure for the synthesis of unsymmetrical ketones utilizing a pyrrole-bearing carbonyl linchpin reagent (carbonyl linchpin N,O-dimethylhydroxylamine pyrrole; CLAmP) is reported. In contrast to other carbonyl dielectrophile equivalents, CLAmP enables the synthesis of ketones from a variety of organolithium and Grignard reagents. The electrophilic nature of CLAmP enables the addition of less reactive as well as thermally unstable nucleophiles. CLAmP was designed to form kinetically stable tetrahedral intermediates upon the addition of organometallic nucleophiles. Evidence for the existence of persistent tetrahedral intermediates was obtained through in situ IR studies.

Highly efficient and environmentally benign preparation of Weinreb amides in the biphasic system 2-MeTHF/water

A straightforward chromatography-free preparation of Weinreb amides starting from acid halides has been achieved in the biphasic medium 2-MeTHF/water. Analytically pure compounds were isolated in excellent yields simply after removal of 2-MeTHF, which abs

4,5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators

The invention is directed to 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor modulators, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, to methods for preparing novel intermediates useful for their syntheses, and to methods for preparing compositions. The invention also relates to the uses of compounds and compositions administered to patients to achieve a therapeutic effect in multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia, emesis, nausea, and gastrointestinal disorders. Compounds of the present disclosure are directed to formula (I): wherein the substituents have the definitions given in the specification.

Efficient Conversions of Carboxylic Acids into O-Alkyl, N-Alkyl and O,N-Dialkylhydroxamic Acids

Carboxylic acids were conveniently converted into unsubstituted, N-alkyl-, O-alkyl-, and O,N-dialkylhydroxamic acids via acylbenzotriazole intermediates. The ready availability of the reagents, mild conditions, and easy handling of the intermediates are advantageous.